A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy.

Carine El Sissy Amos KirilovskyMarc Van den EyndeAna Maria MusinaMaria-Gabriela AniteiAlfredo RomeroFlorence MarliotAudelaure JuncaJérôme DoyenBernhard MlecnikNacilla HaicheurTessa FredriksenChristine LagorceAnne Jouret-Mourin Daniel LeonardFrédéric BibeauSoledad IseasEnrique L RocaAna M CabanneCarlos Alberto VaccaroJuan P SantinoEduardo HuertasDavid TougeronCarlos CarvalhoNuno L FigueiredoRodrigo O PerezAngelita Habr-GamaViorel ScripcariuJean-Pierre GerardJérôme GalonGuy ZeitounFranck Pagès

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

ISB predicts response to nT and survival in patients with LARC treated by surgery. Its usefulness in the selection of patients eligible for a Watch-and-Wait strategy is strongly suggested.

Keyphrases

rectal cancer
end stage renal disease
locally advanced
newly diagnosed
ejection fraction
chronic kidney disease
minimally invasive
peritoneal dialysis
prognostic factors
squamous cell carcinoma
ultrasound guided
acute coronary syndrome
radiation therapy
atrial fibrillation
surgical site infection
patient reported